Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer

Publication Date: April 19, 2023

Key Points

Key Points

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of morbidity and mortality among patients with cancer.

Patients with cancer are significantly more likely to develop VTE than people without cancer and experience higher rates of VTE recurrence and bleeding complications during VTE treatment.

Comprehensive management of VTE in patients with cancer includes both the identification of patients who are most likely to benefit from pharmacologic prophylaxis, as well as effective treatment to reduce the risk of VTE recurrence and mortality.

The current update adds apixaban as an option for the treatment of VTE in patients with cancer, and addresses recent evidence regarding direct factor Xa inhibitors for extended postoperative thromboprophylaxis.

Treatment

...reatmen...

Hospitalized patients who have act...


...patients who have active malignancy wi...


...ne pharmacologic thromboprophylaxis should no...


...logic thromboprophylaxis should not be...


...-risk outpatients with cancer (Khorana sco...


Patients with multiple myeloma rec...


...tients with malignant disease undergoing major s...


...axis with UFH or LMWH should be commence...


...echanical methods may be added to pharmac...


...men of pharmacologic and mechanical prophy...


Pharmacologic thromboprophylaxis for...


...pharmacologic thromboprophylaxis fo...


...Updated) Patients who are candidates...


...ernatively, patients may be offered prophylac...


...ed) Initial anticoagulation may inv...


...Updated) For long-term anticoagulation, LMWH,...


...ation with LMWH, direct factor Xa inhibitors, or...


...n expert opinion in the absence of randomi...


...of a vena cava filter may be offered as an...


...s with primary or metastatic centra...


...and deep vein thrombosis should be treated in the...


...eatment of isolated subsegmental PE or spl...


...icoagulant use is not recommended to improve...


...tantial variation in risk of VTE between individ...


...nd members of the oncology team should educate p...


...arding off-label use in guideline recommend...


...ive Model for Chemotherapy-associated...